GlassScriptPhysician profile
Mark J Marino
NPI 1497861314
$14,659.11
in general payments reported to CMS, 2019-2025
41 companies · $3,449 in 2025
The $3,449 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $924 · 2021: $1,569 · 2022: $2,087 · 2023: $2,673 · 2024: $2,854 · 2025: $3,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,943 · Education: $32.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,942.71 |
| Education | $32.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,446.72 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,597.48 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,384.70 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $984.74 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $908.77 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $667.30 | 2019-2025 | |
| Pfizer INC. | $645.72 | 2019-2025 | |
| Ardelyx, INC. | $617.99 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $589.25 | 2022-2025 | |
| Lilly USA, LLC | $257.44 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $247.34 | 2019-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $242.94 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $239.48 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $186.90 | 2023-2025 | Vegzelma, Yuflyma |
| Madrigal Pharmaceuticals | $184.16 | 2025 | Rezdiffra |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$21,363.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Marino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.